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Abstract
Objectives. To investigate the presence of autoantibodies against mammalian chaperones of the endo-
plasmic reticulum (ER) in patients with RA and other immune-mediated diseases.
Methods. Sera from healthy donors, from early RA patients with two follow-up samples, patients with
SLE, SSc and IBD were collected and analysed for anti-ER chaperone antibodies. Detection of serum IgG
antibodies against immunoglobulin heavy chain binding protein (BiP), glucose-regulated protein 94 (Grp94)
and calnexin was carried out using ELISA. The specificity of sera positive for individual ER chaperones
was confirmed by immunoblotting. Statistical analysis was performed using Welch’s t-test, Mann–Whitney
U-test, partial correlation and Pearson’s correlation.
Results. In patients with RA and SLE, autoantibody titres against BiP, Grp94 and calnexin were signifi-
cantly higher than those in healthy controls. These autoantibodies were detectable in patients with early
RA and titres remained stable for at least 6–12 months. Also several SSc and IBD patients exhibited
autoantibodies against these ER chaperones; however, titres and frequencies were lower than in RA or
SLE patients. Furthermore, anti-calnexin antibodies correlated significantly with the presence of BiP and
Grp94 autoantibodies in patients with RA and SLE.
Conclusion. Calnexin and Grp94 were identified as novel autoantigens in RA and calnexin in SLE. Since
calnexin, Grp94 and BiP are ER-resident proteins of eukaryotic cells, our data suggest that autoantibody
generation against ER chaperones is independent of initial exposure to the corresponding bacterial chap-
erones; rather, ER chaperones may represent genuine autoantigens.
Key words: Rheumatoid arthritis, Systemic lupus erythematosus, Chaperone, Heat shock protein,
Autoantibodies, ELISA, Calnexin, Grp94, BiP.
Introduction
RA is a systemic disorder of largely unknown origin char-
acterized by chronic inflammation of synovial joints, lead-
ing to progressive erosions of cartilage and bone. The
prevalence of RA is 1% of the world’s population with
women being three times more often affected than men
[1]. Serologically, the majority of RA patients are charac-
terized by the presence of RF and antibodies to cyclic
citrullinated peptides (anti-CCPs). RF displays a low spe-
cificity for RA, since RF is also detectable in sera of pa-
tients with other autoimmune diseases, with bacterial
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infections as well as in healthy donors. In contrast,
anti-CCP antibodies are highly specific for RA. Also
other autoantibody specificities were described in RA
including antibodies to keratin (anti-keratin) [2], heteroge-
neous nuclear RNP A2/B1 (anti-hnRNP-A2/-B1 or
anti-RA33) [3] and collagen type II [4–6]. In addition, auto-
antibodies to HSPs, mainly of the 60- and 70-kDa family,
have been described in patients with RA [7, 8], but they
were also found in sera of patients with other autoimmune
diseases such as SLE [9], multiple sclerosis [10, 11], IBD
[12] and Behc¸et’s disease [13]. HSP family members and
mainly those acting as molecular chaperones have been
functionally implicated in immunological dysregulation
[14]. Chaperones prevent irreversible aggregation of pro-
teins under physiological and stress conditions as they
selectively recognize and bind non-native proteins [15].
In addition, endoplasmic reticulum (ER)-resident chaper-
ones, such as immunoglobulin heavy chain binding pro-
tein (BiP), glucose-regulated protein 94 (Grp94) and
calnexin, are involved in antigen recognition and presen-
tation, because they take part not only in folding and as-
sembly of early intermediates of MHC Class I and II
molecules, but also in MHC peptide loading [16, 17].
Furthermore, HSPs have been implicated in immune re-
sponses against pathogens and infectious diseases [18].
It has been postulated that HSPs provide a basis for auto-
immunity in chronic inflammatory diseases, because they
are one of the most conserved protein families [19].
Bacterial infections might therefore induce an immune re-
sponse against prokaryotic HSPs and may lead to
cross-reactivity of T cells and the production of autoanti-
bodies; however, the exact mechanisms remain to be
elucidated.
In the present study, we investigated the presence of
autoantibodies against three major ER chaperones,
namely calnexin, BiP and Grp94, in sera of patients with
RA, SLE, SSc and IBD. The specificities of antibodies to
BiP and calnexin were confirmed by western blotting.
Patients with RA and SLE displayed significantly higher
antibody titres against BiP, Grp94 and calnexin compared
with healthy donors.
Patients, materials and methods
Study population and clinical evaluation
Sera from 155 RA patients [60% female, mean (S.D.) age
58 (14) years] with average disease duration of 6 months
since the onset of first symptoms were collected in 20 col-
laborating rheumatological centres within the German
Network for Competence in Rheumatology. The interval
between each visit was at least 3 months and on average
6 months. All patients fulfilled at least four of the 1987
revised classification criteria for RA [20] at study inclusion,
referred to as Visit 1. Almost 70% of RA patients were
either carriers of one HLA-DR1 or one HLA-DR4 allele.
Sera of 70 sex-matched healthy donors (55% female)
served as control cohort. A cohort of 60 SLE patients
and 22 SSc patients from the Department of Internal
Medicine 3, University of Erlangen-Nuremberg, were
randomly selected irrespective of stage or severity of the
disease. Patients fulfilled the ACR classification criteria
for SLE [21, 22] or for early SSc [23], respectively. The
diagnoses of IBD were made according to the Lennard-
Jones criteria [24]. The study was approved by the
ethical committee of the Friedrich-Alexander-University
Erlangen-Nuremberg, and informed consent was obtained
from all individuals before entering the study.
Serum samples
Venous blood was collected from healthy donors and pa-
tients with RA into serum tubes (S-Monovette, Sarstedt,
Nu¨mbrecht, Germany). To obtain serum, centrifugation
was carried out at 2000g for 10 min at 4C. All serum
samples were stored at 20C.
Purification of HSPs
Canine Grp94 was expressed in Escherichia coli and
purified as described previously [25]. Recombinant
human calnexin was purchased from Stressgen
(SPP-865; Biomol, Hamburg, Germany). The expression
and purification of murine BiP was carried out according
to the protocol of Mayer et al. [26].
Detection of anti-ER chaperone antibodies by ELISA
Autoantibodies directed to calnexin, BiP and Grp94
were assessed by ELISA according to the protocol of
Schellekens et al. [27]. Briefly, Maxisorb polystyrene
96-well plates (Nunc, Wiesbaden, Germany) were coated
with 50 ml/well of 1mg/ml calnexin, BiP and Grp94,
respectively, in PBS and incubated overnight at 4C.
To control for non-specific binding of serum one-half of
each plate was coated with 1mg/ml BSA. After four
washes with PBS-T (0.05% Tween-20) plates were
blocked with 200ml of 2% BSA in phosphate-buffered
saline (PBS; 3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM
KCl, 135 mM NaCl pH 7.4) for 1 h. Serum samples diluted
1 : 40 in RIA buffer [10 mM Tris, pH 7.6, 350 mM NaCl, 1%
BSA, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycho-
late, 0.1% SDS] supplemented with 10% rabbit serum
(Sigma-Aldrich, Munich, Germany) were subjected in du-
plicate (100 ml/well) to each well and incubated for 90 min
at RT. After five washes, 100ml of 1 : 5000 diluted (RIA
buffer) rabbit anti-human immunoglobulin G–horseradish
peroxidase (IgG–HRP) (Dianova, Cat. No. 309-035-082,
Hamburg, Germany) was added to each well and incu-
bated for 1 h at room temperature (RT). After a final wash-
ing step, antibodies were detected using 100ml of a 1 mg/
ml O-phenylenediamine dihydrochloride solution
(Sigma-Aldrich, St Louis, MO, USA). The reaction was
stopped after 15 min with 1 M HCl. The absorbance at
490 nm was measured using a microplate spectropho-
tometer (SPECTRA max 190; Molecular Devices,
Sunnyvale, CA, USA). To compare different plates, a ref-
erence serum from a RA patient that was known to bind
the respective ER chaperone, was carried along on each
96-well plate as internal standard. For calculation of rela-
tive anti-ER chaperone antibody levels, the mean optical
density (OD) of wells coated with BSA as background
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value (non-specific binding) were subtracted from the
mean OD of each sample. For normalization, all values
were finally divided by the mean value obtained for healthy
donors.
SDS–PAGE and western blot analyses
Purified calnexin and BiP were loaded at a concentration
of 0.5 mg/ml in 1 SDS–PAGE sample buffer (60 mM Tris–
HCl, pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol
blue, 1% 2-mercaptoethanol) to reducing 10% SDS slab
gels as described previously [28]. Proteins were trans-
ferred to a polyvinyl difluoride membrane (Millipore,
Bedford, UK) in a semi-dry apparatus (Serva, Heidelberg,
Germany) according to the manufacturer’s instructions.
The membrane was blocked for 1 h at RT with Tris-buffered
saline with Tween-20 (TBS-T) [10 mM Tris, 150 mM NaCl,
0.05% (v/v) Tween-20, pH 7.4] supplemented with 5% milk
powder. Subsequently, blots were incubated for 1 h with
sera from RA patients (diluted 1 : 200 in RIA buffer contain-
ing 5% milk powder), which were found to be either posi-
tive or negative for anti-calnexin or anti-BiP antibodies.
Anti-calnexin and anti-BiP antibodies (both mouse mAbs;
BD Bioscience Pharmingen, San Diego, CA, USA) served
as positive controls in a 1 : 1000 dilution. After washing the
blots were incubated at RT for 1 h with HRP-conjugated
goat anti-mouse IgG or rabbit anti-human IgG–HRP, each
diluted 1 : 10 000 in RIA buffer supplemented with 5% milk
powder. After a final washing step, proteins were detected
using enhanced chemiluminescence (ECL) reagents and
Amersham Hyperfilm ECL (Amersham Biosciences,
Freiburg, Germany).
Sequence analysis
Protein sequence alignments based on Swiss-Prot infor-
mation and calculation of sequence identities for canine
(P41148) and human (P14625) Grp94 as well as murine
(P20029) and human (P11021) BiP were carried out
using ClustalW software (Conway Institute, UCD Dublin,
Ireland) [29]. For visualization of results the CLC Free
Workbench 4 software package (CLC bio, Aarhus,
Denmark) was used.
Statistical analyses
Comparison of means of anti-ER chaperone autoantibody
titres between healthy donors and patients with RA and
SLE were computed using Welch’s test coefficients be-
cause variances were not assumed to be equal according
to Levene’s F-test; moreover, both groups had n> 30
implying Gaussian distribution of sample means accord-
ing to the central limit theorem. Means of anti-ER chaper-
one antibody titres for SSc and IBD patients as well
as for the subgroups of men and women had to
be analysed for Gaussian distribution of sample means
via Lilliefors-corrected Kolmogorov–Smirnov test as the
individual groups now comprised only 22 subjects
or fewer. If Gaussian distribution of sample means could
be assumed, Welch’s t-test was used; otherwise
Mann–Whitney U-test had to be applied.
Partial correlation of antibody titres was performed to
test whether high values of calnexin correspond to high
titres of BiP or Grp94 in patients with RA, SLE and healthy
donors, while controlling for possible mediator variables
such as age and gender. For RA patients, retest reliability
of antibody titres from at least two visits was also
analysed by bivariate Pearson correlation for calnexin,
BiP and Grp94 titres over time. Statistical analysis
was done using Predictive Analytics Software (PASW)
Version 17.0.2 (SPSS Inc., Chicago, IL, USA). P4 0.05
was considered to be statistically significant.
Results
Canine Grp94 and murine BiP share high similarity
with their human orthologues
First, we investigated whether our assay system, using
recombinantly expressed canine Grp94, murine BiP and
human calnexin, was suitable to detect autoantibodies in
human sera. Highly purified human proteins are currently
not available, thus we used canine Grp94 and murine BiP.
According to multiple sequence alignments, canine and
human Grp94 are 97.9% identical and 99.4% similar to
each other, and the identity and similarity between murine
and human BiP is 98.5 and 99.1%, respectively (Fig. 1A
and B).
Due to this high-sequence conservation, it was very
likely that human serum antibodies would recognize the
mammalian orthologues in a respective ELISA system. In
an explorative ELISA analysis, we detected antibodies to
BiP and calnexin in patients with RA. To ensure the reli-
ability of our testing system, it was necessary to deter-
mine whether autoantibodies in RA sera recognize BiP
and calnexin specifically. Therefore, highly purified cal-
nexin and BiP were loaded onto SDS–PAGE and sera
that had been tested either positive or negative for
anti-calnexin (Fig. 2A) or anti-BiP antibodies (Fig. 2B) by
ELISA were applied to the blotted membrane. Incubation
with negative serum did not result in a signal, whereas
with positive serum specific bands were detected for cal-
nexin and BiP. Specific mAbs to calnexin and BiP served
as positive controls.
Autoantibodies to BiP, Grp94 and calnexin are
elevated in sera of patients with RA and SLE
After assessing the suitability of our antigens and validat-
ing the specificity of our ELISA method by western blot,
analyses of autoantibodies against the ER chaperones
BiP, Grp94 and calnexin in sera of patients with various
autoimmune and inflammatory diseases such as RA, SLE,
SSc and IBD and in healthy donors was carried out. As
summarized in Table 1 and Fig. 3, we found increased
levels of autoantibodies of the IgG isotype for all three
ER chaperones in patients with RA and SLE as compared
with healthy donors. In contrast, similar anti-ER chaper-
one autoantibody titres were found for patients with IBD
and healthy donors. SSc patients displayed significantly
increased concentrations of anti-Grp94 autoantibodies.
After Bonferroni correction, all antibody titres mentioned
www.rheumatology.oxfordjournals.org 2257
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above remained significantly different when compared
with healthy controls apart from Grp94 titres in SSc.
Our data confirmed a significantly increased antibody
response to BiP in patients with RA and to Grp94 in SLE
patients, as reported previously [30–32]. Our observation
of significantly increased Grp94 and calnexin autoanti-
body titres in patients with RA and calnexin in patients
with SLE is novel (Fig. 3B and C and Table 1).
Furthermore, statistical analysis using Pearson correl-
ation for retest reliability of individual anti-ER chaperone
autoantibody titres at different timepoints (Visits 1–3)
revealed that autoantibodies to all three ER chaperones
remained constant at each follow-up visit without major
changes (Fig. 4). The Pearson correlation coefficients
were highly significant for autoantibodies to BiP (r= 0.80;
P< 0.001) and Grp94 (r= 0.86; P< 0.001) in two visits and
for calnexin over three visits (r= 0.92; P< 0.001). Hence,
we conclude that autoantibody titres against BiP, Grp94
and calnexin remain stable over a period of at least 6–
12 months. Furthermore, the autoantibody response
against BiP, Grp94 and calnexin is a rather early
event in RA, since the first serum samples (Visit 1) of RA
patients were obtained as early as 6 months after disease
onset.
High mutual correlation of autoantibodies against
ER chaperones
As autoantibody titres against calnexin, BiP and Grp94
were found to be significantly increased in patients with
RA and SLE, we analysed the co-existence of these
TABLE 1 Statistical analysis of antibodies to calnexin, BiP and Grp94 detected in patients with RA, SLE, SSc and IBD
compared with healthy donors
Autoantibodies
against n Mean (S.D.), AU 95% CI P-value
Calnexin
NHD 63 1.01 (0.81) 0.81, 1.22
RA Visit 1 119 1.83 (1.73) 1.51, 2.14 <0.001*
SLE 60 3.04 (3.98) 2.01, 4.07 <0.001*
SSc 22 1.07 (1.00) 0.62, 1.51 NS**
IBD 14 0.88 (0.66) 0.50, 1.26 NS*
BiP
NHD 70 1.22 (1.27) 0.92, 1.52
RA Visit 1 131 2.95 (3.73) 2.31, 3.40 <0.001*
SLE 60 2.45 (1.60) 2.04, 2.87 <0.001*
SSc 22 1.32 (0.70) 1.01, 1.63 NS*
IBD 14 1.63 (1.27) 0.89, 2.36 NS**
Grp94
NHD 70 1.07 (1.00) 0.83, 1.31
RA Visit 1 131 1.77 (1.82) 1.45, 2.08 0.001*
SLE 60 2.43 (3.68) 1.48, 3.38 0.007*
SSc 22 2.34 (2.75) 1.13, 3.56 0.04**
IBD 14 0.74 (1.11) 0.10, 1.38 NS**
P-values for RA, SLE, SSc and IBD patients were calculated in comparison with NHD. *P-values were calculated using Welch
t-test. **P-values were calculated using Mann–Whitney U-test. AU: arbitrary units; NHD: normal healthy donor; NS: not
significant.
FIG. 2 Specific recognition of calnexin (A) and BiP (B) by antibodies that are contained in sera of RA patients. Western
blotting of purified calnexin (A) and BiP (B) was carried out. Sera, previously identified by ELISA to contain either high or
no anti-calnexin or anti-BiP autoantibody titres were selected and termed as positive and negative sera, respecitvely.
mAbs to calnexin and BiP served as internal positive controls.
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autoantibody specificities by partial correlation and con-
trolled these relationships for the influence of age and
gender. Table 2 displays a highly significant correlation
between antibodies to calnexin and those to BiP and to
Grp94 in at least two visits of patients with RA.
Similarly, the presence of autoantibodies against these
three ER chaperones correlated with each other in
patients with SLE (Table 3). Partial correlation was also
performed for healthy donors, although very few healthy
donors displayed elevated anti-ER chaperone antibody
titres. The appearance of anti-calnexin and anti-Grp94
FIG. 3 Detection of autoantibodies to BiP (A), Grp94
(B) and calnexin (C) in sera of patients with RA, SLE, SSc
and IBD compared with healthy donors. Autoantibodies to
mammalian BiP, Grp94 and calnexin in sera of RA patients
with consecutive visits (Visit 1: n= 131; Visit 2: n= 81; Visit
3: n= 68), SLE patients (n= 60), SSc patients (n= 22),
patients with IBD (n= 14) and healthy controls (n= 70)
were analysed by ELISA. For detection of antibodies to
IgG-type murine BiP, canine Grp94 and human calnexin
wells was coated and ELISAs were carried out as has
been described in detail in the ‘Patients, materials and
methods’ section. Data points represent the percentage
of the mean of the healthy donors. Statistical analysis was
performed using Welch’s t-test for RA and SLE patients
and Mann–Whitney U-test for SSc and IBD patients if
Gaussian distribution could not be assumed.
FIG. 4 Anti-BiP (A), anti-Grp94 (B) and anti-calnexin
(C) antibody profiles of patients with RA of consecutive
visits. Autoantibodies to BiP, Grp94 and calnexin were
analysed by ELISA in sera of RA patients with consecutive
visits. Antibody titres in arbitrary units are shown in natural
logarithmic scale with linked dots for the same patient of
consecutive visits.
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antibodies seems to be synchronized also at lower levels,
as the partial correlation was significant (Table 3).
Anti-ER chaperone antibodies did not correlate with
serological and clinical parameters of RA diagnosis such
as the presence of anti-CCP antibodies, RF, with disease
activity measured by 28-joint DAS (DAS-28) or RA sus-
ceptibility alleles, namely HLA-DR1 and HLA-DR4 (data
not shown).
Discussion
In this study, we identified the ER chaperones calnexin
and Grp94 as novel autoantigens in RA as well as calnexin
in SLE. Autoantibodies against Grp94 have been
described very recently in SLE patients [30–32]. Patients
with RA and SLE had significantly higher titres of autoan-
tibodies against calnexin, BiP and Grp94 compared with
healthy donors or with patients with SSc or IBD. The se-
lection of calnexin, BiP and Grp94 as potentially new anti-
gens was based on the following considerations: (i) BiP
appears to be involved in the pathogenesis of experimen-
tal arthritides, since immunization or tolerance induction
with BiP markedly influenced the disease course [31];
(ii) due to their essential chaperone function, HSPs play
an important role in proper MHC folding and peptide load-
ing and certain MHC alleles have been associated with RA
[33, 34]; and (iii) calnexin, BiP and Grp94 are ER-resident
proteins of eukaryotic cells. With respect to the immuno-
genic mechanism, a bacterial trigger for induction of auto-
antibody generation against Grp94 or BiP cannot be
completely excluded. However, cross-reactivity to pro-
karyotic HSP and chaperone family members is unlikely.
With regard to Grp94 and BiP, bacteria express solely the
cytoplasmic representatives HtpG and DnaK that belong
to the family of Hsp90 and Hsp70, respectively. The iden-
tity between human Grp94 and HtpG from E. coli is 32%,
whereas human BiP shows 46% identical stretches with
DnaK from E. coli or Streptococcus pneumoniae (data not
shown). Likewise, a bacterial infection as initial trigger for
autoantibody production against calnexin is extremely un-
likely, since calnexin is entirely restricted to eukaryotic
cells.
In 1986, Srivastava et al. [35] reported induction of an
anti-tumour immune response by immunization of mice
with tumour-derived Grp94. These experiments created
the basis for further investigations on cytosolic and ER
chaperones that have been shown to bind antigenic pep-
tides generated within the cells. Chaperones transport
and load these peptides to the MHC Class I and II
molecules and, therefore, interact physically with MHC I
and II molecules [33, 34, 36]. Under yet undefined patho-
logical circumstances, ER chaperones, or fragments of ER
chaperones, might be displayed on the cell surface by
hijacking the MHC II surface transport machinery.
Selective proteolysis, especially for chaperones such as
BiP and Hsp60 in peripheral blood mononuclear cells of
RA patients has been described, providing a putative
mechanism for the generation of neoantigens [37].
The generation of antibodies against calnexin, BiP and
Grp94 seems at least to be independent of the presence
TABLE 2 Partial correlation for anti-ER chaperone antibodies in patients with RA controlled for gender and age
Partial correlation
controlled for
gender and age
RA
Calnexin BiP Grp94 Calnexin BiP Grp94
Visit 1 Visit 1 Visit 1 Visit 2 Visit 2 Visit 2
RA Calnexin
Visit 1
rpartial
P-value
n
BiP
Visit 1
rpartial 0.213**
P-value 0.022
n 115
Grp94
Visit 1
rpartial 0.579** 0.548**
P-value 0 0
n 115 127
Calnexin
Visit 2
rpartial 0.914** 0.444** 0.856**
P-value 0 0.004 0
n 71 79 79
BiP
Visit 2
rpartial 0.444** 0.830** 0.519** 0.375**
P-value 0.001 0 0 0.001
n 70 78 78 78
Grp94
Visit 2
rpartial 0.819** 0.569** 0.894** 0.802** 695**
P-value 0 0 0 0 0
n 70 78 78 78 78
Calnexin
Visit 3
rpartial 0.917** 0.458** 0.791** 0.869** 0.428** 0.807**
P-value 0 0 0 0 0.001 0
n 53 61 61 67 61 61
**P< 0.01 (two-tailed).
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of HLA-DR1 and HLA-DR4 alleles, because no correlation
between HLA-DR1- or HLA-DR4-positive RA patients and
the generation of anti-ER chaperone antibodies was
observed. Interestingly, antibodies against ER chaper-
ones were detectable already early during the disease
course of RA within the first 3–12 months after onset of
symptoms, and their titres remained stable. Hence, auto-
immunity to ER chaperones might not be just a conse-
quence of long-lasting tissue destruction in RA. Rather,
anti-ER chaperone immune responses could be involved
in the pathogenic process. Moreover, antibodies against
calnexin, BiP and Grp94 also occur in the absence of RF
or anti-CCP antibodies, suggesting that antibodies to
these ER chaperones might represent a useful novel
diagnostic tool in RA, especially in those lacking RF
or anti-CCP antibodies.
Rheumatology key messages
. Sera from patients with RA and SLE contain signifi-
cantly higher anti-calnexin, anti-BiP and anti-Grp94
antibody titres than healthy donors.
. ER chaperone autoantibody titres mutually correlate
in RA and SLE patients.
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